Add time:08/11/2019         Source:sciencedirect.com

The anticoagulant and estrogenic effects of hexolame, N-(3-hydroxy-1,3,5(10)-estratrien-17β-yl)-6-hydroxyhexylamine, are described. A single subcutaneous injection of hexolame in adult and infant male mice produced dose-dependent increases in blood clotting time which could be observed even after 2 days. In ovariectomized mice, hexolame produced vaginal cornification (estrogenic response). The data suggested that if used in the treatment of prostatic cancer, hexolame, like prolame, would not induce cardiovascular accidents. It could also be useful in the prevention of thrombosis. (Steroids 55:83–86, 1990)

We also recommend Trading Suppliers and Manufacturers of hexolame (cas 110346-23-1). Pls Click Website Link as below: cas 110346-23-1 suppliers